Treatment of chronic hepatitis C: A systematic review

Geetanjali Chander, Mark S. Sulkowski, Mollie W. Jenckes, Michael Torbenson, H. Franklin Herlong, Eric B. Bass, Kelly A. Gebo

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

This systematic review addressed 3 issues regarding current treatments for chronic hepatitis C: (1) efficacy and safety in treatment-naive patients; (2) efficacy and safety in selected subgroups of patients; and (3) effects on long-term clinical outcomes. Electronic databases were searched for articles from January 1996 to March 2002. Additional articles were identified by searching references in pertinent articles and recent journals and by questioning experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, or clinical outcome measures. For data collection, paired reviewers assessed the quality of each study and abstracted data. This systematic review found that the combination of high-dose peginterferon and ribavirin was more efficacious than standard interferon and ribavirin in persons infected with hepatitis C virus (HCV) genotype 1 (sustained virologic response [SVR] rate: 42% vs. 33%) and that ranges of SVR rates were higher with peginterferon than standard interferon monotherapy in naive patients (10% to 39% vs. 3% to 19%). Reports were consistent in showing treatment with interferon and ribavirin was more efficacious than interferon monotherapy in treatment-naive persons and previous nonresponders and relapsers. Studies were moderately consistent in showing that treatment decreases the risk for hepatocellular carcinoma (HCC). The evidence on treatment in important subgroups was limited by a lack of randomized controlled trials. Thus, the combination of Peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment.

Original languageEnglish (US)
Pages (from-to)S135-S144
JournalHepatology
Volume36
Issue number5
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Ribavirin
Interferons
Therapeutics
Hepacivirus
Genotype
Safety
Hepatitis C
Hepatocellular Carcinoma
Randomized Controlled Trials
Outcome Assessment (Health Care)
Databases
Sustained Virologic Response

ASJC Scopus subject areas

  • Hepatology

Cite this

Chander, G., Sulkowski, M. S., Jenckes, M. W., Torbenson, M., Herlong, H. F., Bass, E. B., & Gebo, K. A. (2002). Treatment of chronic hepatitis C: A systematic review. Hepatology, 36(5), S135-S144. https://doi.org/10.1053/jhep.2002.37146

Treatment of chronic hepatitis C : A systematic review. / Chander, Geetanjali; Sulkowski, Mark S.; Jenckes, Mollie W.; Torbenson, Michael; Herlong, H. Franklin; Bass, Eric B.; Gebo, Kelly A.

In: Hepatology, Vol. 36, No. 5, 01.11.2002, p. S135-S144.

Research output: Contribution to journalArticle

Chander, G, Sulkowski, MS, Jenckes, MW, Torbenson, M, Herlong, HF, Bass, EB & Gebo, KA 2002, 'Treatment of chronic hepatitis C: A systematic review', Hepatology, vol. 36, no. 5, pp. S135-S144. https://doi.org/10.1053/jhep.2002.37146
Chander G, Sulkowski MS, Jenckes MW, Torbenson M, Herlong HF, Bass EB et al. Treatment of chronic hepatitis C: A systematic review. Hepatology. 2002 Nov 1;36(5):S135-S144. https://doi.org/10.1053/jhep.2002.37146
Chander, Geetanjali ; Sulkowski, Mark S. ; Jenckes, Mollie W. ; Torbenson, Michael ; Herlong, H. Franklin ; Bass, Eric B. ; Gebo, Kelly A. / Treatment of chronic hepatitis C : A systematic review. In: Hepatology. 2002 ; Vol. 36, No. 5. pp. S135-S144.
@article{e3bccc0b207b43dd96462681a4db78c8,
title = "Treatment of chronic hepatitis C: A systematic review",
abstract = "This systematic review addressed 3 issues regarding current treatments for chronic hepatitis C: (1) efficacy and safety in treatment-naive patients; (2) efficacy and safety in selected subgroups of patients; and (3) effects on long-term clinical outcomes. Electronic databases were searched for articles from January 1996 to March 2002. Additional articles were identified by searching references in pertinent articles and recent journals and by questioning experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, or clinical outcome measures. For data collection, paired reviewers assessed the quality of each study and abstracted data. This systematic review found that the combination of high-dose peginterferon and ribavirin was more efficacious than standard interferon and ribavirin in persons infected with hepatitis C virus (HCV) genotype 1 (sustained virologic response [SVR] rate: 42{\%} vs. 33{\%}) and that ranges of SVR rates were higher with peginterferon than standard interferon monotherapy in naive patients (10{\%} to 39{\%} vs. 3{\%} to 19{\%}). Reports were consistent in showing treatment with interferon and ribavirin was more efficacious than interferon monotherapy in treatment-naive persons and previous nonresponders and relapsers. Studies were moderately consistent in showing that treatment decreases the risk for hepatocellular carcinoma (HCC). The evidence on treatment in important subgroups was limited by a lack of randomized controlled trials. Thus, the combination of Peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment.",
author = "Geetanjali Chander and Sulkowski, {Mark S.} and Jenckes, {Mollie W.} and Michael Torbenson and Herlong, {H. Franklin} and Bass, {Eric B.} and Gebo, {Kelly A.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1053/jhep.2002.37146",
language = "English (US)",
volume = "36",
pages = "S135--S144",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C

T2 - A systematic review

AU - Chander, Geetanjali

AU - Sulkowski, Mark S.

AU - Jenckes, Mollie W.

AU - Torbenson, Michael

AU - Herlong, H. Franklin

AU - Bass, Eric B.

AU - Gebo, Kelly A.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - This systematic review addressed 3 issues regarding current treatments for chronic hepatitis C: (1) efficacy and safety in treatment-naive patients; (2) efficacy and safety in selected subgroups of patients; and (3) effects on long-term clinical outcomes. Electronic databases were searched for articles from January 1996 to March 2002. Additional articles were identified by searching references in pertinent articles and recent journals and by questioning experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, or clinical outcome measures. For data collection, paired reviewers assessed the quality of each study and abstracted data. This systematic review found that the combination of high-dose peginterferon and ribavirin was more efficacious than standard interferon and ribavirin in persons infected with hepatitis C virus (HCV) genotype 1 (sustained virologic response [SVR] rate: 42% vs. 33%) and that ranges of SVR rates were higher with peginterferon than standard interferon monotherapy in naive patients (10% to 39% vs. 3% to 19%). Reports were consistent in showing treatment with interferon and ribavirin was more efficacious than interferon monotherapy in treatment-naive persons and previous nonresponders and relapsers. Studies were moderately consistent in showing that treatment decreases the risk for hepatocellular carcinoma (HCC). The evidence on treatment in important subgroups was limited by a lack of randomized controlled trials. Thus, the combination of Peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment.

AB - This systematic review addressed 3 issues regarding current treatments for chronic hepatitis C: (1) efficacy and safety in treatment-naive patients; (2) efficacy and safety in selected subgroups of patients; and (3) effects on long-term clinical outcomes. Electronic databases were searched for articles from January 1996 to March 2002. Additional articles were identified by searching references in pertinent articles and recent journals and by questioning experts. Articles were eligible for review if they reported original human data from a study that used virological, histological, or clinical outcome measures. For data collection, paired reviewers assessed the quality of each study and abstracted data. This systematic review found that the combination of high-dose peginterferon and ribavirin was more efficacious than standard interferon and ribavirin in persons infected with hepatitis C virus (HCV) genotype 1 (sustained virologic response [SVR] rate: 42% vs. 33%) and that ranges of SVR rates were higher with peginterferon than standard interferon monotherapy in naive patients (10% to 39% vs. 3% to 19%). Reports were consistent in showing treatment with interferon and ribavirin was more efficacious than interferon monotherapy in treatment-naive persons and previous nonresponders and relapsers. Studies were moderately consistent in showing that treatment decreases the risk for hepatocellular carcinoma (HCC). The evidence on treatment in important subgroups was limited by a lack of randomized controlled trials. Thus, the combination of Peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment.

UR - http://www.scopus.com/inward/record.url?scp=0036829986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036829986&partnerID=8YFLogxK

U2 - 10.1053/jhep.2002.37146

DO - 10.1053/jhep.2002.37146

M3 - Article

C2 - 12407587

AN - SCOPUS:0036829986

VL - 36

SP - S135-S144

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -